| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 27 | 49.8x | 17.8x | Bottom tier | |
Growth | 74 | 77.4% | 7.1% | Top tier | |
Quality | 82 | 7.9% | 4.5% | Top tier | |
Safety | 91 | — | 2.6x | Top tier | |
Capital Return | 54 | — | 2.12% | Around median | |
Momentum | 77 | 9.9% | 2.9% | Top tier | |
Sentiment | 33 | 4 | 3 | Bottom tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Omada Health provides virtual healthcare between doctor visits for chronic conditions through its Prevention, Diabetes, Hypertension, Weight Health, GLP-1, and Cholesterol programs, in addition to other programs on its platform. The company reaches members through employers, health plans, and pharmacy benefit managers, and as of the end of December 2025, it was connected to coverage for more than 25 million eligible people and had commercial relationships with the three largest pharmacy benefit managers in the United States. Its revenue model is based primarily on the care activity a member receives rather than a fixed subscription, and trailing 12-month revenue per member was $284 in fiscal 2026 Q2, compared with $279 a year earlier.
Omada recorded record revenue of $88 million in fiscal 2026 Q2, representing 43% year-over-year growth and 13% sequential growth, with approximately 1.1 million total members, up 45% year over year. GAAP gross margin was 73%, compared with 66% a year earlier, while non-GAAP gross margin was 74%, compared with 68%. The company also generated net income of more than $5 million and adjusted EBITDA of $11 million, compared with a net loss of approximately $5 million and adjusted EBITDA near breakeven in the corresponding period.
The growth mix was driven by the GLP-1 care track, increased use of multiple cardiometabolic programs, and improved enrollment effectiveness. The Diabetes and Hypertension programs also grew by more than 50%, exceeding the overall revenue growth rate of 43%. These two programs are among Omada's highest-priced offerings, and their members remain in care for longer periods, while the percentage of GLP-1 members remained close to its level in fiscal 2025 Q4, when they numbered 150 thousand out of 887 thousand total members. EDGAR data for the trailing 12 months shows revenue of $345.8 million, gross profit of $234.3 million, and net income of $14.7 million, despite recording a net loss of $3 million in fiscal 2026 Q1.
Automated analysis for informational purposes only — not investment advice.
The average analyst price target is $25.63, with a consensus rating of “Buy,” and target estimates range from $18 to $35. The average is approximately 4.8% below the 52-week high of $26.915, while the low is $10.28. No displayed P/E multiple is available, despite trailing 12-month net income reaching $14.7 million and earnings per share reaching approximately $0.249, so the valuation is closely tied to the sustainability of revenue and margin growth after the expected moderation in the second half of fiscal 2026.
Figures in the text are as of 2026-09-01; the live price is shown at the top of the page.
Omada's revenue rose 43% year over year to $88 million and 13% compared with fiscal 2026 Q1. Growth came from the GLP-1 care track, increased use of multiple programs within the cardiometabolic portfolio, and improved enrollment effectiveness. The Diabetes and Hypertension programs grew by more than 50%, while total membership increased 45% to approximately 1.1 million. Conversion from email campaigns to enrollments also improved by approximately 20% compared with the corresponding period.
Fiscal 2026 Q2 data does not indicate sole dependence on GLP-1, as the Diabetes and Hypertension programs were the fastest-growing, with growth rates exceeding 50%. In fiscal 2025 Q4, GLP-1 members numbered approximately 150 thousand out of 887 thousand members, and management said on August 6, 2026, that this percentage remained approximately stable through fiscal 2026 Q2. The platform also includes Prevention, Cholesterol, GLP-1 Flex Care, and the Prescription program. However, employers' decisions regarding coverage of GLP-1 medications remain an important factor in the demand mix.
Omada generated net income of more than $5 million and adjusted EBITDA of $11 million in fiscal 2026 Q2, compared with a net loss of approximately $5 million and adjusted EBITDA near breakeven a year earlier. This was the second quarter in which it achieved GAAP net income, after fiscal 2025 Q4. Trailing 12-month data shows net income of $14.7 million and earnings per share of approximately $0.249. By contrast, fiscal 2026 Q1 recorded a net loss of $3 million, meaning consistent profitability across all quarters has not yet been established.
The agreement expands the Prevention and Hypertension programs to an additional 1.5 million people within HCSC's fully insured business in three states. The launch will begin during the 2027 benefits cycle, and management expects revenue recognition to begin during the first half of fiscal 2027. The programs are embedded directly in the benefit and therefore do not require a subsequent sales cycle with each employer. The expansion builds on an existing relationship that included HCSC's self-funded business and fully insured programs in other states.
The company raised its revenue guidance to $334–340 million from a previous range of $322–330 million. The midpoint of the new range represents growth of approximately 30% compared with fiscal 2025. It also raised its adjusted EBITDA guidance to $21–27 million from $14–20 million, representing an improvement of approximately $18 million at the midpoint compared with fiscal 2025. Management expects growth to moderate in the second half of fiscal 2026 because of enrollment seasonality and the strength of the comparison period.
Wei-Li Shao will become CEO of Omada on January 1, 2027, after serving as president for more than four years and joining the company seven years ago as chief commercial officer. Co-founder and CEO Sean Duffy will transition on the same date to executive chair of the board. Duffy will remain a member of the management team, focusing on long-term strategy, partnerships, and other opportunities. The transition was announced during the fiscal 2026 Q2 earnings call on August 6, 2026.
